ArticleMedeniyet medical journal2024
The Serum Biomarkers in Ulcerative Colitis.
Article in Medeniyet medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, the aim was to evaluate the diagnostic effectiveness of more easily applicable and cost-effective serum biomarkers, such as neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), C-reactive protein (CRP) to albumin ratio (CAR), and CRP-to-lymphocyte ratio (CLR), instead of the endoscopic activity index (EAI) used to determine disease activation in ulcerative colitis (UC) patients. Methods: Blood tests performed during the same period as colonoscopy were reviewed, and NLR, PLR, CAR, and CLR values were calculated. Based on the EAI score, patients with a score <4 were classified as having UC in remission, those with a score ≥4 as having active UC, and those with normal colonoscopy results as the control group. Results: The study included 66 patients with active UC, 31 with UC in remission, and 99 controls. The CLR and CAR values of active and remission UC patients were found to be higher compared with the control group (p<0.001), while no significant difference was found between the groups in terms of PLR and NLR values (p>0.05). The AUC calculated for CLR in diagnosing active UC was significant (p<0.001), and the best cut-off value was determined as >1,75. For CAR, the best cut-off value was calculated as >0.11. Conclusions: This study demonstrated that the CLR and CAR had high sensitivity and specificity for detecting UC activity, whereas the PLR and NLR had low diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.